AbCellera Biologics WKN: A2QKXS ISIN: CA00288U1066 Kürzel: ABCL Forum: Aktien Thema: Hauptdiskussion
4,51
EUR
-0,39 % -0,02
9. Mai 2026, 12:58 Uhr,
Lang & Schwarz
Kommentare 1.501
H
Hopper58,
28.02.2025 7:08 Uhr
0
https://www.fool.com/earnings/call-transcripts/2025/02/27/abcellera-biologics-abcl-q4-2024-earnings-call-tra/?source=djc&utm_source=djc&utm_medium=feed&utm_campaign=article&referring_guid=f034da26-791b-4857-8beb-d36d70f8d5c7&mod=mw_quote_news
H
Hopper58,
28.02.2025 7:06 Uhr
0
TD Cowen Keeps Their Buy Rating on AbCellera Biologics (ABCL)
TipRanks Auto-Generated Intelligence Newsdesk
Feb 28, 2025, 02:55 AM
TD Cowen Keeps Their Buy Rating on AbCellera Biologics (ABCL)
TD Cowen analyst Brendan Smith maintained a Buy rating on AbCellera Biologics (ABCL – Research Report) yesterday. The company’s shares closed yesterday at $2.92.
According to TipRanks, Smith is a 3-star analyst with an average return of 4.1% and a 47.62% success rate. Smith covers the Healthcare sector, focusing on stocks such as Halozyme, Repligen, and Ginkgo Bioworks Holdings.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AbCellera Biologics with a $4.00 average price target. https://www.tipranks.com/news/blurbs/td-cowen-keeps-their-buy-rating-on-abcellera-biologics-abcl?mod=mw_quote_news
H
Hopper58,
26.02.2025 16:29 Uhr
0
What To Expect From AbCellera Biologics Inc (ABCL) Q4 2024 Earnings
Feb. 26, 2025 at 7:55 a.m. ET on GuruFocus.com
AbCellera Biologics Inc (ABCL, Financial) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue is $7.58 million, and the earnings are expected to come in at -$0.15 per share. The full year 2024's revenue is expected to be $31.58 million, and the earnings are expected to be -$0.59 per share. More detailed estimate data can be found on the Forecast page.
AbCellera Biologics Inc (ABCL, Financial) Estimates Trends
Revenue estimates for AbCellera Biologics Inc (ABCL) have remained steady at $31.58 million for the full year 2024. For 2025, revenue estimates have increased from $43.13 million to $43.35 million over the past 90 days. Earnings estimates for AbCellera Biologics Inc (ABCL) have stayed constant at -$0.59 per share for the full year 2024 and at -$0.70 per share for 2025 over the past 90 days. https://www.gurufocus.com/news/2715974/what-to-expect-from-abcellera-biologics-inc-abcl-q4-2024-earnings?r=4bf001661e6fdd88d0cd7a5659ff9748&mod=mw_quote_news
A
All_in_long,
15.02.2025 6:59 Uhr
0
🔜 😎🚀💰💰💰,💰💰$
Arras,
14.02.2025 13:07 Uhr
0
Und wann geht hier mal was ??
Arras,
23.01.2025 1:20 Uhr
0
Hoffentlich geht 1 Prozent davon in abcellera rein dann haben wir 5mrd Wert also x5 das wäre Traum
P
PG911,
22.01.2025 18:28 Uhr
0
mega :) danke dir
Thypolicon69,
22.01.2025 17:55 Uhr
0
Trump 500 Mrd Ki
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | AbCellera Biologics Hauptdiskussion | ||
| 2 | Daytrader ABCellera📈 |
Meistdiskutiert
|
|
Thema | ||
|---|---|---|---|
| 1 | RHEINMETALL Hauptdiskussion | -0,01 % | |
| 2 | Diginex | -2,31 % | |
| 3 | OTL nach dem RS 1:20 | -0,26 % | |
| 4 | TELADOC HEALTH INC.DL-001 Hauptdiskussion | +0,03 % | |
| 5 | INTEL Hauptdiskussion | -0,24 % | |
| 6 | XRP zu USD Hauptdiskussion | +0,21 % | |
| 7 | GAMESTOP Hauptdiskussion | +0,24 % | |
| 8 | NEL ASA Hauptdiskussion | ±0,00 % | |
| 9 | SIVERS IMA HLDG Hauptdiskussion | ±0,00 % | |
| 10 | INTELLIA THERAPEU DL-,01 Hauptdiskussion | +0,25 % | Alle Diskussionen |
Aktien
|
|
Thema | ||
|---|---|---|---|
| 1 | RHEINMETALL Hauptdiskussion | -0,01 % | |
| 2 | Diginex | -2,31 % | |
| 3 | OTL nach dem RS 1:20 | -0,26 % | |
| 4 | TELADOC HEALTH INC.DL-001 Hauptdiskussion | +0,03 % | |
| 5 | INTEL Hauptdiskussion | -0,24 % | |
| 6 | New Highland Critical Minerals Registered (A) Hauptdiskussion | -2,33 % | |
| 7 | NEL ASA Hauptdiskussion | ±0,00 % | |
| 8 | SIVERS IMA HLDG Hauptdiskussion | ±0,00 % | |
| 9 | INTELLIA THERAPEU DL-,01 Hauptdiskussion | +0,25 % | |
| 10 | RENK (für normale, sachliche Kommunikation!) | ±0,00 % | Alle Diskussionen |